SCHEMBL5654572

SCHEMBL5654572

CCCCCCCCCCCCCCCC[NH+](CCCCCCCCCCCCCCCC)c1c(F)c(F)c(F)c(F)c1F.Fc1c(F)c(F)c([B-](c2c(F)c(F)c(F)c(F)c2F)(c2c(F)c(F)c(F)c(F)c2F)c2c(F)c(F)c(F)c(F)c2F)c(F)c1F

nearest known ligand 0.34

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5088208 1.00 DNM1 (0.34) DNM1
SCHEMBL3982956 1.00 DNM1 (0.34) DNM1
SCHEMBL7638293 0.88
SCHEMBL3988431 0.84
SCHEMBL7561743 0.83 DNM1 (0.38) DNM1
SCHEMBL6065603 0.83 DNM1 (0.38) DNM1
SCHEMBL2695539 0.83 DNM1 (0.38) DNM1
SCHEMBL5653553 0.83
Octane SCHEMBL29076189 0.82 TSHR (0.42) DNM1
SCHEMBL2694955 0.81 DNM1 (0.41) DNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098356-B2 Substituted indenyl metal complexes and polymerization process DOW GLOBAL TECHNOLOGIES INC. (US) 2006-08-29 US claimed
US-20050143536-A1 Substituted indenyl metal complexes and polymerization process DOW GLOBAL TECHNOLOGIES LLC 2005-06-30 US claimed
EP-1497301-A1 SUBSTITUTED POLYCYCLIC, FUSED RING METAL COMPLEXES AND POLYMERIZATION PROCESS Dow Global Technologies Inc. (US) 2005-01-19 EP claimed
US-20050010039-A1 Polycyclic fused heteroring compounds metal complexes and polymerization process GRAF DAVID D (US) 2005-01-13 US claimed
EP-1487886-A1 SUBSTITUTED INDENYL METAL COMPLEXES AND POLYMERIZATION PROCESS Dow Global Technologies Inc. (US) 2004-12-22 EP claimed
US-6806327-B2 POLYMERIZATION CATALYSTS SUCH AS (8-METHYLENE-1,8-DIHYDRODIBENZO(E,H)AZULEN-1-YL)-N-(1,1-DIMETHYLETHYL) DIMETHYLSILANAMIDE TITANIUM (II) 1,4-DIPHENYL-1,2-BUTADIENE DOW GLOBAL TECHNOLOGIES INC. 2004-10-19 US claimed
WO-2003089444-A1 SUBSTITUTED POLYCLIC, FUSED RING METAL COMPLEXES AND POLYMERIZATION PROCESS DOW GLOBAL TECHNOLOGIES INC. (US) 2003-10-30 WO claimed
WO-2003078483-A1 SUBSTITUTED INDENYL METAL COMPLEXES AND POLYMERIZATION PROCESS DOW GLOBAL TECHNOLOGIES INC. (US) 2003-09-25 WO claimed
US-20020151662-A1 Substituted polycyclic, fused ring compounds, metal complexes and polymerization process DOW GLOBAL TECHNOLOGIES LLC 2002-10-17 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143536-A1 Substituted indenyl metal complexes and polymerization process ORC3, SOD1, YAP1 DNM1 2055/4885
US-20050010039-A1 Polycyclic fused heteroring compounds metal complexes and polymerization process PICALM, AP1M1, PCBP1 DNM1 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.